Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients

Updated Erleada Data Shows Reduced Risk of Death in Prostate Cancer Patients

Source: 
BioSpace
snippet: 

Treatment with Erleada plus androgen deprivation therapy resulted in a 25% reduction in the risk of death compared to placebo in prostate cancer patients, Janssen announced at the 2019 European Society for Medical Oncology (ESMO) Congress today.